Company news

Ensysce Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

April 17, 2022

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 30, 2022

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

March 23, 2022

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

February 7, 2022

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

January 18, 2022

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid

January 9, 2022

Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference

January 4, 2022

Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614

January 3, 2022

Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection

December 14, 2021

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

November 29, 2021

Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

November 14, 2021

Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing

November 7, 2021

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

October 25, 2021

Ensysce Biosciences Announces $15 Million Convertible Note Financing

September 26, 2021

Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614

September 7, 2021

Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

August 15, 2021

Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”

August 4, 2021

Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

July 25, 2021

Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021

July 20, 2021

Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection

July 7, 2021

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.